Robert Califf, MD, current deputy commissioner for medical products and tobacco at the FDA, has been nominated to lead the FDA and take over as commissioner. Margaret Hamburg, MD, stepped down from the position in February after nearly 6 years at the helm.
President Barack Obama has announced his nomination to lead the FDA: Robert Califf, MD, the current deputy commissioner for medical products and tobacco at the FDA. If the Senate confirms the nomination, Dr Califf would take the reins as the new commissioner for food and drugs.
In February, Margaret Hamburg, MD, announced she was stepping down, and since then Stephen Ostroff, MD, the FDA's chief scientist has filled the position. At the time, there had been speculation when Dr Califf's appointment with the FDA was first announced in January 2015 that he was part of the FDA's succession plan and would eventually become the next FDA commissioner.
“Dr Califf’s deep knowledge and experience in the areas of medicine and clinical research will enable the agency to capitalize on, and improve upon, the significant advances we’ve made in medical product development and regulation over the last few years,” Dr Hamburg had
said in a statement upon Dr Califf’s appointment as deputy commissioner.
Dr Califf has spent most of his career in academia, having spent more than 30 years as a prominent cardiologist and medical researcher at Duke University. However, he has some experience with the FDA, having served on the agency's Cardiorenal Advisory Panel from 1996 to 2000 and its Science Board Working Group from 2007 to 2008.
Among the issues Dr Califf will have to tackle as commissioner are unfinished tobacco regulations, food safety and labeling reforms, and pressure from Republicans in Congress to streamline drug reviews.
The White House announced the nomination Tuesday along with a number of other officials being nominated for various federal positions.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen